Minneapolis, MNNCT07286292Now EnrollingIRB Ready

Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation Clinical Trial in Minneapolis, MN

Access cutting-edge grade 2 astrocytoma or oligodendroglioma with an idh1 or idh2 mutation treatment through this phase 2 clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.

Sponsored by Institut de Recherches Internationales Servier (I.R.I.S.)

Quick Self-Assessment

See if you qualify for this Minneapolis location

Preparing your pre-screening questions…

Expert Care in Minneapolis

Access grade 2 astrocytoma or oligodendroglioma with an idh1 or idh2 mutation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related grade 2 astrocytoma or oligodendroglioma with an idh1 or idh2 mutation treatment provided free

Apply for This Minneapolis Location

Check if you qualify for this grade 2 astrocytoma or oligodendroglioma with an idh1 or idh2 mutation clinical trial in Minneapolis, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Minneapolis

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Minneapolis site if eligible
  4. 4Begin participation

About This Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation Study in Minneapolis

The objective of this study is to evaluate the safety, tolerability, efficacy profile, and effect on growth and development of vorasidenib in pediatric participants aged 12 to \< 18 years old with grade 2 glioma with an IDH1 or IDH2 mutation. The study includes a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up period and a long-term follow-up period. The long-term follow-up period will assess participants for growth, development, and long-term safety impacts for approximately 5 years after the start of treatment or until Tanner Stage V is reached (whichever is later). Participants may undergo blood tests, heart tests (electrocardiogram (ECG)), imaging (MRI, X-ray), vital sign checks, and physical exams.

Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.)

Who Can Participate

Inclusion Criteria

Weigh ≥ 25 kg at Screening.
Written informed consent/assent must be obtained from a legally authorized representative, and assent must be obtained from the participant in accordance with local regulations. Participants and their families must be willing and able to comply with the scheduled visits, treatment plans, procedures, and laboratory tests, including serial peripheral blood sampling, during the study.
Have Grade 2 astrocytoma or oligodendroglioma per World Health Organisation (WHO) 2021 criteria.
Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, gross-total resection) and no other prior anticancer therapy, including chemotherapy and radiotherapy, and do not need immediate chemotherapy or radiotherapy in the opinion of the Investigator.
Confirmed IDH1 or IDH2 gene mutation, as well as known 1p19q and/or ATRX (Alpha Thalassemia/Mental Retardation Syndrome X-linked) status based on local testing of tumor tissue by an accredited laboratory.
For astrocytoma: Absence of 1p19q co-deletion and/or documented loss of nuclear ATRX expression or ATRX mutation by local testing.
For oligodendroglioma: Presence of 1p19q co-deletion by local testing.
Have magnetic resonance imaging (MRI)-evaluable, measurable, non-enhancing disease
Have a Karnofsky Performance Score (KPS; for participants ≥ 16 years of age) or Lansky Play-Performance Scale (LPPS; for participants \< 16 years of age) score of ≥ 70. Karnofsky Performance Score and LPPS \< 70 due to functional limitations as a result of prior surgical resections or due to the anatomical location of the tumor will be permitted.
Have adequate bone marrow function as evidenced by:
Absolute neutrophil count ≥ 1500/mm3 or ≥ 1.5 × 109/L
Hemoglobin ≥ 9 g/dL
Platelets ≥ 100,000/mm3 or ≥ 100 × 109/L
Have adequate hepatic function as evidenced by:
Serum total bilirubin ≤ 1.5 × ULN; if \> 1.5 ULN and due to Gilbert syndrome, total bilirubin ≤ 3 × ULN with direct bilirubin ≤ ULN
AST at or below ULN and ALT at or below ULN
Alkaline phosphatase (ALP) ≤ 2.5 × ULN
Have adequate renal function as evidenced by:
Serum creatinine ≤ 2.5 × ULN, OR
eGFR \> 40 mL/min/1.73 m2 based on the Bedside Schwartz method 0.413 × (Height in cm/Serum Creatinine in mg/dL)
Have recovered from any clinically relevant toxicities associated with any prior surgery for the treatment of glioma unless stabilized under medical management (functional limitations as a result of prior surgical resections or due to the anatomical location of the tumor will be permitted).
Female participants of reproductive potential must have a negative serum pregnancy test before starting investigational medicinal product (IMP).
Women of childbearing potential as well as fertile male participants with female partners of reproductive potential, must agree to abstain from sexual intercourse or to use 2 effective methods of contraception from screening until at least 90 days after the last dose of IMP.

Exclusion Criteria

Have had any prior anticancer therapy other than surgery (biopsy, sub-total resection, gross-total resection) for treatment of glioma including, but not limited to, systemic chemotherapy, radiotherapy, vaccines, small molecule inhibitors, IDH inhibitors, and investigational agents.
Have features assessed as high-risk by the Investigator.
Have leptomeningeal disease.
Concurrent active malignancy except for curatively resected nonmelanoma skin cancer or curatively treated carcinoma in situ. Participants with previously treated malignancies are eligible provided they have been disease-free for 3 years at Screening.
Unable to swallow oral medication.
Are pregnant or breastfeeding.
Are participating in another interventional study at the same time; participation in non-interventional registries or epidemiological studies is allowed.
Have a severe or uncontrolled active acute or chronic infection or an unexplained fever \> 38.5°C within 7 days of C1D1.
Have a known hypersensitivity to any of the components of vorasidenib.
Have significant active cardiac disease within 6 months before the start of IMP, including New York Heart Association Class III or IV congestive heart failure, myocardial infarction, unstable angina, and/or stroke.
Have a heart-rate corrected QT interval using Fridericia's formula (QTcF) ≥ 450 msec or other factors that increase the risk of QT prolongation or arrhythmic events.
Are taking therapeutic doses of steroids (defined as \> 1.5 mg/day dexamethasone or \>10 mg/day prednisone or equivalent) for signs/symptoms of glioma. Participants taking physiologic doses (defined as ≤ 1.5 mg/day dexamethasone or ≤ 10 mg/day prednisone or equivalent) for medical conditions not related to glioma will be permitted.
Are taking any medications that are CYP2C19 or CYP3A substrates with a narrow therapeutic index or strong inhibitors of CYP1A2.
Have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, known positive human immunodeficiency virus (HIV) antibody results, or AIDS-related illness. Participants with a sustained viral response to HCV treatment or immunity to prior HBV infection will be permitted. Participants with chronic HBV or HIV that is adequately suppressed by institutional practice will be permitted.
Have known active inflammatory gastrointestinal disease, chronic diarrhea, previous gastric resection or lap band dysphagia, short-gut syndrome, gastroparesis, or other condition that limits the ingestion or gastrointestinal absorption of drugs administered orally. Gastroesophageal reflux disease under medical treatment is allowed (assuming no drug interaction potential).
Have any other acute or chronic medical or psychiatric condition.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT07286292) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation Treatment Options in Minneapolis, MN

If you're searching for grade 2 astrocytoma or oligodendroglioma with an idh1 or idh2 mutation treatment options in Minneapolis, MN, this clinical trial (NCT07286292) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced grade 2 astrocytoma or oligodendroglioma with an idh1 or idh2 mutation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all grade 2 astrocytoma or oligodendroglioma with an idh1 or idh2 mutation clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Minneapolis, MN

See all brain cancer clinical trials recruiting in Minneapolis — not just this study.

Browse Brain Cancer Trials in Minneapolis →

Browse More Trials by Condition

Brain Cancer TrialsAlzheimers Disease TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Minneapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Minneapolis, MN